Seamon, Leigh G
Java, James J
Monk, Bradley J
Penson, Richard T
Brown, Jubilee
Mannel, Robert S
Oaknin, Anna
Leitao, Mario M
Eisenhauer, Eric L
Long, Harry J
Liao, Shu Y
Tewari, Krishnansu S
Article History
Received: 25 June 2017
Revised: 1 October 2017
Accepted: 12 October 2017
First Online: 28 November 2017
Change Date: 23 January 2018
Change Type: Update
Change Details: This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
Competing interests
: All the authors cite no relevant conflicts of interest related to this manuscript, except as noted below: Dr(s) Tewari (study chair/principal investigator for GOG 240), Penson (quality of life chair for GOG 240), Oaknin (Spain chair through GEICO for GOG 240), and Monk (senior author of GOG 240 and chair of the Cervix Cancer Committee of the NRG Oncology Cooperative Group and co-chair of the Gynaecologic Cancer Intergroup) were members of the scientific steering committee that conducted GOG 240. To participate in the regulatory discussions through which bevacizumab could potentially be approved for women struggling with advanced cervical cancer, these authors as well as author Eisenhauer participated on 1-2 advisory boards held by Roche/Genentech. Monk, Penson, and Tewari subsequently joined the Roche/Genentech speaker’s bureau to help review appropriate patient selection and management of bevacizumab-related adverse events with the oncology community. The institutions where Monk, Oaknin, and Tewari practice have contracted research grants with Roche/Genentech to conduct trials evaluating the anti-PD-L1 agent, atezolizumab. Roche/Genentech contracted research with institution: Monk, Oaknin, Tewari; Roche/Genentech Advisory Boards participation: Monk, Penson, Eisehauer, Tewari; Roche/Genentech Speaker’s Bureau: Monk, Penson, Tewari.